Retrophin Secures $4,000,000 Series A Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    330 Madison Avenue 6th Floor New York, NY 10017
  • Company Description
    Retrophin, LLC is a privately-held New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The company intends to invest the proceeds from the Series A financing to advance its pipeline of novel rare-disease drug candidates, including a proof-of-concept study of RE-021 (a dual acting receptor antagonist of Angiotensin and Endothelin receptors) in Focal Segmental Glomerulosclerosis (FSGS) scheduled to begin enrolling patients during the second quarter of this year.
  • M&A Terms
  • Venture Investor
    MSMB Capital
  • Venture Investor

Trending on Xconomy